Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ABBV · NYSE · Pharmaceuticals
AbbVie (ABBV) · oqro.io/stocks/ABBV · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Baskets of the companies that insiders, members of Congress or funds recently reported buying, each held under a written rule.
No open-market purchase by an insider of AbbVie was filed in the last 90 days. The latest on record was on Mar 30, 2020.
Since 2013, AbbVie insiders reported 25 open-market purchases and 538 sales on Forms 4 and 5, with purchases in 5 different years, most recently 2020.
In the last 90 days, 1 insider of AbbVie (ABBV) reported 1 open-market sale worth $11.9M in total on SEC Form 4. The largest seller by value was Jeffrey Ryan Stewart, with $11.9M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 12 trades in AbbVie (ABBV) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Pete Sessions (TX17), Sen. Alan Armstrong, Rep. Josh Gottheimer (NJ05) and 3 other members.
AbbVie's next results are expected on Feb 2, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$286.01−6.81 (−2.33%)
Close of Nov 18, 2026, vs Nov 17 · end-of-day, not a live quote
+22.3% (+$52.14) from Nov 18, 2025 to Nov 18, 2026 · adjusted daily closes
Adjusted close went from $233.87 on Nov 18, 2025 to $286.01 on Nov 18, 2026 (+22.3%). Disclosed in this range: 7 insider trades, 0 pre-arranged insider sales, 5 Congress trades, and 380 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Medicines including Humira and Skyrizi.
Last 12 months
+22.3%
Market value
$506B
S&P 500 +10.6% over the same dates. Prices adjusted for splits and dividends.
Short interest: 15.8M shares sold short (0.9% of shares outstanding), +1.5% vs the previous count, 3.3 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.
Revenue
$17.4B
+10.3% vs the same quarter a year earlier
Free cash flow, last 12 months
$18.9B
This quarter $7.3B, a year earlier $6.64B
Net debt
$61.5B
Debt $72.2B, cash $10.8B, at Sep 30, 2026
Net income, last 12 months
$10.3B
Operating profit covers interest 7.1x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Oct 30, 2026.
Revenue, fiscal 2025
$61.2B
+8.6% vs the year before
Net income, fiscal 2025
$4.23B
As reported in the annual filing
Shares outstanding
1.77B
As of Oct 26, 2026
In fiscal 2025 the company spent $980M buying back its own shares and $11.7B on dividends. Cash actually paid, from its cash-flow statement.
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Azita Saleki-Gerhardt (Officer) plans to sell ~$4.02M of AbbVie
Insider selling
Their largest sale since 2020Traded Nov 9 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −2.5% · S&P 500 −3.0% · to Nov 18
AbbVie's CHIEF COMMERCIAL OFFICER sold $11.9M of AbbVie shares. The filing does not indicate a pre-arranged trading plan.
Jeffrey R Stewart (Officer) plans to sell ~$11.9M of AbbVie
Planned, from payCongress
Traded Sep 14 · disclosed 4 days later
Since the trade +9.3% · S&P 500 −4.0% · to Nov 18
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
On the public record for AbbVie over the 12 months to Nov 19, 2026: 15 FDA records, 1 WARN notice and 118 clinical trials (5th most among listed companies).
Insiders of AbbVie reported 25 open-market purchases and 538 sales since 2013; purchases in 5 different years, most recently 2020.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $30.8M7×7 trades |
| 2025 | — | $68.8M25×25 trades |
| 2024 | — | $143M20×20 trades |
| 2023 | — | $58.4M34×34 trades |
| 2022 | — | $136M43×43 trades |
| 2021 | — | $99.6M26×26 trades |
| 2020 | $667K6×6 trades | $65.8M15×15 trades |
| 2019 | $12.9M10×10 trades | $4.45M4×4 trades |
| 2018 | $596K2×2 trades | $53.5M25×25 trades |
| 2017 | $282K1×1 trade | $97.8M109×109 trades |
| 2016 | — | $42.8M61×61 trades |
| 2015 | — | $19M125×125 trades |
| 2014 | — | $1.72M30×30 trades |
| 2013 | $157K6×6 trades | $8.99M14×14 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Top officer leaving
“(“AbbVie”), notified the Company’s Board of Directors (the “Board”), of her intent to resign from the Board, effective November 2, 2026, in light of her recent appointment as Chief Executive Officer at Align Technology, Inc.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Determination That DIBENZYLINE (Phenoxybenzamine Hydrochloride) Oral Capsule, 10 Milligrams, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Determination That CARAFATE (Sucralfate) Oral Suspension, 1 Gram/10 Milliliters, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation
Notice · International Trade Commission
Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
Notice · Food and Drug Administration
Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
Notice · Food and Drug Administration
Determination That RECTIV (Nitroglycerin) Ointment, 0.4%, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
Notice · Food and Drug Administration
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Against the S&P 500 over the year
Since Nov 14, 2025, ABBV is up 26.0% and the index fund is up 9.0%: 17 points ahead of the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ABBV moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
Anyone owning more than 5% must file within days. Structured filings have existed since December 2024, so older stakes that were never amended may be missing.
Short sale volume: 30.0% of the volume reported to FINRA over the last 20 trading days was marked short, below its 1-year average of 45.8%. FINRA daily files, to Nov 18, 2026.
Fails to deliver: 21K shares (about $5.94M) were not delivered on time for settlement on Oct 28, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.
4 notices filed with state agencies, covering 144 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
88 certified in FY2026 Q3, vs 86 a year earlier. 88 positions in total, median offered wage $139K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
14 approvals or clearances and 1 recall recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Last results
Oct 30, 2026
Within the 30 days after it, until Nov 29, 2026
Next results, expected
Feb 2, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
37%
7 of 19 insider purchases since 2017 came within 30 days after a results announcement
From AbbVie's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know AbbVie's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
74 active phase 3 trials and 63 active phase 2 trials led by this company, mostly in multiple myeloma, crohn's disease, atopic dermatitis. The ones with the nearest registered primary completion date still ahead:
17 trials have a registered primary completion date that has already passed. That usually means the data are being analyzed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.